Tag Archives: ezetimibe

Introduction Ischaemic heart disease is the leading cause of death globally, responsible for 13% of all deaths in 2021.1 Acute coronary syndrome (ACS) represents a key opportunity for secondary prevention to reduce the risk of recurrent cardiovascular (CV) events.2 Lipid-lowering therapy (LLT) is central to this, with elevated levels of low-density lipoprotein cholesterol (LDL-C) being a key initiating factor in atherosclerosis:3 every 1 mmol/L reduction is associated with an approximate 22% decrease in the risk of major CV events.4 For patients with ACS, the National Institute for Health and Care Excellence (NICE) recommends:5,6 Early initi

GISSI-HF shows benefit for PUFA in heart failure Two new studies from the Italian GISSI group show that n-3 polyunsaturated fatty acids (PUFA) supplementation improves morbidity and mortality in those with symptomatic heart failure, but statins don’t have any benefit in the same type of patients. The results were presented during a hotline session at the Congress and published simultaneously in The Lancet (Lancet 2008; DOI:10.1016/S0140-6736[08]61239-8, and Lancet 2008;DOI:10.1016/S0140-6736[08]61240-4). Long-term administration of PUFA reduced all-cause mortality by 9%, which the investigators say was a modest effect, and they also cut

The ENHANCE study compared two years of treatment with ezetimibe/simvastatin 10/80 mg versus simvastatin 80 mg alone in 720 FH patients. The primary end point was the mean change in the intima-media thickness (IMT) measured at three sites in the carotid arteries.  This showed no statistically significant difference between treatment groups, with the change from baseline being 0.0111 mm for the ezetimibe/simvastatin group versus 0.0058 mm for the simvastatin alone group (p=0.29). Key secondary imaging end points, cardiac events and adverse events were also not different between the two groups. Ezetimibe was, however, associated with a greater

No content available

No content available